Gerpevir – capsules, lyophilisate, suspension, tablets
Inside, intravenously.
To prevent relapses of Herpes simplex, patients with immunodeficiency are prescribed 200 mg 4 times a day every 6 hours. In case of severe immunodeficiency (after bone marrow transplantation or in case of impaired absorption from the intestine) - 400 mg 5 times a day.
Children over 6 years old - 800 mg 4 times a day; 2-6 years - 400 mg 4 times a day; under 2 years - 200 mg 4 times a day. More accurately, the dose can be determined at the rate of 20 mg/kg, but not more than 800 mg 4 times a day. The course of treatment is 5 days.
For children from 3 months to 12 years, the dose for intravenous administration is determined based on body area: infections caused by the Herpes simplex virus - 250 mg/sq.m of body surface every 8 hours; reduced immunity, herpetic encephalitis, chickenpox, herpes zoster - 500 mg/sq.m.
Inside. Genital herpes: initial therapy - 200 mg every 4 hours while awake, 5 times a day for 10 days;
recurrent genital herpes (less than 6 episodes per year), intermittent therapy - 200 mg every 4 hours while awake, 5 times a day for 5 days;
recurrent genital herpes (more than 6 episodes per year), long-term suppressive therapy - 400 mg 2 times a day or 200 mg 3-5 times a day.
Herpes simplex of the skin and mucous membranes (treatment): 200-400 mg 5 times a day for 10 days in patients with impaired immunity.
Herpes simplex of the skin and mucous membranes (prevention): 400 mg every 12 hours.
Herpes zoster: 800 mg every 4 hours while awake, 5 times a day for 7-10 days.
Chicken pox: 800 mg 4 times a day for 5 days. Treatment should begin at the earliest signs or symptoms of chickenpox.
For chronic renal failure, dose adjustment is necessary depending on the size of the CK and the required dosing regimen for normal renal function: normal renal function and chronic renal failure with CK more than 10 ml/min - 200 mg every 4 hours, 5 times a day CK less than 10 ml/min - 200 mg every 12 hours;
normal renal function, chronic renal failure with creatinine clearance more than 10 ml/min - 400 mg every 12 hours, with creatinine clearance less than 10 ml/min - 200 mg every 12 hours;
normal renal function, chronic renal failure with CK more than 25 ml/min - 800 mg every 4 hours while awake, 5 times a day, CK 10-25 ml/min - 800 mg every 8 hours, CK less than 10 ml/min - 800 mg every 12 hours
Children under 2 years of age - the dose has not been determined. However, when studying the drug, no unusual toxic effects or specific pediatric problems were identified in children receiving acyclovir in doses of up to 3 g/m2 and 80 mg/kg per day.
Children 2-12 years old, weighing up to 40 kg, with chickenpox: orally, 20 mg/kg, up to 800 mg per dose, 4 times a day for 5 days.
Children 2-12 years old, weighing 40 kg or more, with chickenpox: adult dose.
IV drip (administered at a constant rate for at least 1 hour).
Severe genital herpes, initial therapy: adults and children over 12 years of age - 5 mg/kg every 8 hours for 5 days; children under 12 years old - 250 mg/sq.m every 8 hours for 5 days.
Herpes simplex of the skin and mucous membranes in patients with impaired immunity: adults and children over 12 years old - 5-10 mg/kg every 8 hours for 7 days; children under 12 years old - 250 mg/sq.m every 8 hours for 7 days.
Encephalitis caused by the Herpes simplex virus: adults and children over 12 years of age - 10 mg/kg every 8 hours for 10 days; children from 3 months to 12 years - 20 mg/kg every 8 hours for 10 days.
Herpes zoster in patients with impaired immunity: adults and children over 12 years of age - 10 mg/kg every 8 hours for 7 days; children under 12 years of age - 20 mg/kg every 8 hours for 7 days.
Generalized infection in newborns caused by the Herpes simplex virus: newborns and children under 3 months - 10 mg/kg every 8 hours for 10 days. A dose of 15-20 mg/kg every 8 hours can be used, but the effectiveness and safety of such doses have not been established.
For chronic renal failure in adults and children, a dose reduction and/or change in the interval between administration is required: CC more than 50 ml/min, dose - 100%, interval - 8 hours; CC 25-50 ml/min, dose - 100%, interval - 12 hours; CC 10-25 ml/min, dose - 100%, interval - 24 hours; CC less than 10 ml/min, dose - 50%, interval - 24 hours.
The maximum dose for adults when administered intravenously is 30 mg/kg or 1.5 g/m2/day.
Gerpevir 2.5% 5 g ointment
Instructions for the use of the drug for specialists GERPEVIR Trade name Gerpevir International nonproprietary name Acyclovir Dosage form Ointment 2.5%, 5 g Composition 1 g of ointment contains the active substance - acyclovir in terms of dry matter 0.025 g, excipients: proxanol 268, propylene glycol, polyethylene oxide 400, emulsifier No. 1. Description Homogeneous ointment of white color, with a slight specific odor Pharmacotherapeutic group Other antimicrobial drugs for external use. Antiviral drugs. Acyclovir. ATC code D06BB03 Pharmacological properties Pharmacokinetics When used externally, it is practically not absorbed into the systemic circulation and does not have a systemic effect. When applying the ointment to the affected area of the skin, a therapeutic concentration of the drug is created in it, which is maintained at a constant level for at least 5 hours. Pharmacodynamics Gerpevir is an analogue of the purine nucleoside deoxyguanidine, a component of DNA (deoxyribonucleic acid). The drug is especially effective against herpes simplex and shingles viruses. The similarity of the structures of herpevir and deoxyguanidine allows it to interact with viral enzymes, which leads to an interruption of the virus reproduction cycle. After herpevir is introduced into a cell affected by herpes, under the influence of thymidine kinase secreted by the virus, it is converted into acyclovir monophosphate. Acyclovir monophosphate is converted by host cell enzymes into acyclovir diphosphate. After which, it is converted into the active form of acyclovir triphosphate, which selectively blocks the synthesis of viral DNA. Acyclovir triphosphate has virtually no effect on DNA replication of the host (human) cell. Herpevir for herpes prevents the formation of new rash elements, reduces the likelihood of skin dissemination and visceral complications, accelerates the formation of crusts, and reduces pain in the acute phase of herpes zoster. Indications for use: herpetic lesions of the skin and external mucous membranes (herpes of the lips, external genitalia) caused by Herpes simplex viruses types 1 and 2, Varicella zoster - primary and recurrent herpetic infections in patients with immunodeficiency. Directions for use and dosage: For external use only! It is recommended to use rubber gloves or finger caps to prevent the spread of infection. Treatment should be prescribed when the first symptoms of a herpes infection occur. The ointment is applied to the affected skin and external mucous membranes. Before applying the ointment, the affected surface must be washed with soap and water and dried thoroughly. The ointment is applied in a thin layer at the following rate (for adults): a 1.25 cm strip of ointment should be applied to 25 cm2 of the affected area 4-5 times a day and rubbed in with light movements for 1 minute. Children from 3 months. up to 12 years of age, the ointment is applied in a thin layer at the rate of acyclovir 250 mg/m2 of body surface. The ointment should also be applied to areas bordering the affected surface. The ointment must be applied regularly; in cases where you miss the next application, you should not double the dose the next time you use the drug. It is recommended to complete the full course of treatment - 10 days, even if the symptoms of the disease disappear before the specified period. If there is no effect when applied externally, it is recommended to prescribe the drug in tablet form for oral administration. Side effects - burning sensation, mild pain at the site of the lesion, itching - if it comes into contact with the internal mucous membranes, inflammation may develop Contraindications - hypersensitivity to Gerpevir - infectious diseases with similar symptoms, but caused by other pathogens - pregnancy and lactation - children under 3 months Drug interactions Probenecid slows down the elimination of the drug - the half-life is extended. The interaction of Gerpevir with other drugs that are also used topically has not been studied. Special instructions Gerpevir is used as soon as possible after the first symptoms of herpes appear. Protect affected areas from irritation. Avoid sexual intercourse if one of your sexual partners has symptoms of herpes. Do not allow the ointment to come into contact with the mucous membranes of the mouth, nose, eyes, or vagina. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms. Not studied. Overdose Symptoms: erythema, peeling, burning sensation, burns are possible in areas where the ointment is applied for a long time. Treatment: drug withdrawal. Release form and packaging Ointment 2.5%, 5 g in a tube, 1 tube in a cardboard box. Storage conditions Store in a dry place at a temperature from +8 °C to +15 °C. Keep out of the reach of children! Shelf life 3 years Do not use after the expiration date indicated on the package Conditions for dispensing from pharmacies Without a prescription Manufacturer OJSC “Kievmedpreparat” Ukraine, 01032, Kiev, st. Saksaganskogo, 139 tel./fax; 216-14-74.
Gerpevir tablets 200 mg, 20 pcs.
The tablet should be taken whole with water. When using high doses of acyclovir, an adequate level of hydration should be maintained.
Adults Treatment of infections caused by the herpes simplex virus.
To treat infections caused by the herpes simplex virus, it is necessary to take acyclovir tablets at a dose of 200 mg 5 times a day at approximately 4-hour intervals, with the exception of the night period.
Treatment should last 5 days, but in case of severe primary infection it can be continued.
For patients with severe immunodeficiency (for example, after bone marrow transplantation) or for patients with reduced intestinal absorption, the dose can be doubled to 400 mg or the appropriate dose can be used intravenously.
Treatment should begin as soon as possible after the onset of infection. In the case of recurrent herpes, it is better to start treatment in the prodromal period or after the first signs of skin lesions appear.
Prevention of relapses (suppressive therapy) of infections caused by the herpes simplex virus
In patients with normal immunity, to prevent relapses of infections caused by the herpes simplex virus, take acyclovir tablets at a dose of 200 mg 4 times a day with a 6-hour interval.
For convenience, most patients can take 400 mg of acyclovir 2 times a day at 12-hour intervals.
Treatment will be effective even after discontinuation of tableted acyclovirado 200 mg, which is taken 3 times a day with an 8-hour interval or even 2 times a day with a 12-hour interval.
In some patients, radical improvement is observed after taking a daily dose of acyclovir 800 mg.
To monitor possible changes in the natural course of the disease, drug therapy should be periodically interrupted at intervals of 6-12 months.
Prevention of infections caused by herpes simplex virus
To prevent infections caused by the herpes simplex virus, patients with immunodeficiency should take acyclovir tablets at a dose of 200 mg 4 times a day with a 6-hour interval. For patients with significant immunodeficiency (for example, after bone marrow transplantation) or in patients with reduced intestinal absorption, the dose can be doubled to 400 mg or the appropriate dose can be used intravenously. The duration of prophylaxis depends on the length of the risk period.
Treatment of chickenpox and herpes zoster
To treat infections caused by chickenpox and herpes zoster viruses, you need to take acyclovir tablets at a dose of 800 mg 5 times a day at 4-hour intervals, with the exception of the night period. Treatment should continue for 7 days. In patients with severe immunodeficiency (for example, after bone marrow transplantation) or patients with reduced absorption in the intestine, it is better to use intravenous administration. Treatment should begin as soon as possible after the onset of the disease; the result will be better if treatment is started immediately after the appearance of the rash.
Elderly patients
The possibility of renal impairment in elderly patients should be borne in mind, and the dose for them should be adjusted accordingly (see section "Renal failure"). It is necessary to maintain an adequate level of body hydration.
Kidney failure
Acyclovir should be administered with caution to patients with renal failure. It is necessary to maintain an adequate level of body hydration. In the prevention and treatment of infections caused by the herpes simplex virus in patients with renal failure, recommended oral doses do not lead to the accumulation of acyclovir, the level of which would exceed the safe level established for intravenous administration. However, for patients with severe renal failure (creatinine clearance less than 10 ml/min), it is recommended to set the dose to 200 mg 2 times a day with an interval of approximately 12 hours.
When treating infections caused by the Varicella zoster virus (chickenpox and herpes zoster) for patients with significantly reduced immunity, it is recommended for severe renal failure (creatinine clearance less than 10 ml/min) to set a dose of 800 mg 2 times a day at approximately 12-hour intervals, and for patients with moderate renal failure (creatinine clearance within 10-25 ml/min) - 800 mg 3 times a day with an interval of approximately 8 hours.
Children. Acyclovir tablets are used for children from 2 years of age.
For the treatment and prevention of infections caused by the herpes simplex virus in children with immunodeficiency from 2 years of age, doses as for adults can be used. For the treatment of chickenpox in children over 6 years of age, prescribe 800 mg of acyclovir 4 times a day; children from 2 to 6 years of age can receive 400 mg of acyclovir 4 times a day. The duration of treatment is 5 days.
More accurately, the dose can be calculated based on the child’s body weight - 20 mg/kg body weight per day (not to exceed 800 mg) of acyclovir, divided into 4 doses.
There are no specific data on the use of acyclovir for the prevention (prevention of relapses) of infections caused by the herpes simplex virus, or for the treatment of infections caused by the herpes zoster virus in children with normal immunity.
